Agios Pharmaceuticals, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for AGIO, updated each market day.
AGIO AI Sentiment
AI sees no strong directional signal for Agios Pharmaceuticals, Inc. stock over the next 10 market days.
Prediction date: May 20, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Sector
Exchange
Market Cap
$1,708,619,326
Cap Tier
Employees
540
Headquarters
CAMBRIDGE, MA
Listed Since
July 24, 2013
Website
AGIO Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AGIO Volatility
Agios Pharmaceuticals, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
